BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Baker, Emma K ^a,b   Taylor, Scott ^a   Gupte, Ankita ^a   Sharp, Phillip P ^c   Walia, Mannu ^a   Walsh, Nicole C ^a,b   Zannettino, Andrew C W ^d,e   Chalk, Alistair M ^a,b   Burns, Christopher J ^b,c   Walkley, Carl R ^a,b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

(+)-JQ1 COMPOUND; ANTINEOPLASTIC AGENT; AZEPINE DERIVATIVE; CYCLIN DEPENDENT KINASE; MYC PROTEIN; PROTEIN C FOS; PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FRA 1; TRIAZOLE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE CHECKPOINT; DOWN REGULATION; DRUG EFFECTS; DRUG POTENTIATION; GENE SILENCING; HUMAN; METABOLISM; MOUSE; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZEPINES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; DOWN-REGULATION; DRUG SYNERGISM; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; OSTEOSARCOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 84928975378     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10120     Document Type: Article

References (58)

1. Bacci, G. et al. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur. J. Cancer 41, 2836-2845 (2005).
2. Allison, D. C. et al. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012, 704872 (2012).
3. Kaste, S. C., Pratt, C. B., Cain, A. M., Jones-Wallace, D. J. & Rao, B. N. Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer 86, 1602-1608 (1999).
4. Janeway, K. A. & Grier, H. E. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol 11, 670-678 (2010).
5. Birch, J. M. et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20, 4621-4628 (2001).
6. Chen, X. et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 7, 104-112 (2014).
7. Wadayama, B. et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res. 54, 3042-3048 (1994).
8. Martin, J. W. et al. Digital Expression Profiling Identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as Potential Predictive Biomarkers for Neo-Adjuvant Chemotherapy Response in Paediatric Osteosarcoma. PLoS One 9, e95843 (2014).
9. Sadikovic, B. et al. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer 10, 202 (2010).
10. Sadikovic, B. et al. Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum. Mol. Genet. 18, 1962-1975 (2009).
11. Scionti, I. et al. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Ann. Oncol. 19, 1500-1508 (2008).
12. Shimizu, T. et al. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 29, 5687-5699 (2010).
13. Ueda, T., Healey, J. H., Huvos, A. G. & Ladanyi, M. Amplification of the MYC Gene in Osteosarcoma Secondary to Paget's Disease of Bone. Sarcoma 1, 131-134 (1997).
14. Won, K. Y., Park, H. R. & Park, Y. K. Prognostic implication of immunohistochemical Runx2 expression in osteosarcoma. Tumori 95, 311-316 (2009).
15. Jain, M. et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297, 102-104 (2002).
16. Gamberi, G. et al. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 55, 556-563 (1998).
17. Wang, Z. Q. et al. Bone and haematopoietic defects in mice lacking c-fos. Nature 360, 741-745 (1992).
18. Grigoriadis, A. E., Schellander, K., Wang, Z. Q. & Wagner, E. F. Osteoblasts are target cells for transformation in c-fos transgenic mice. J. Cell Biol. 122, 685-701 (1993).
19. Fleischmann, A. et al. Fra-1 replaces c-Fos-dependent functions in mice. Genes. Dev. 14, 2695-2700 (2000).
20. Eferl, R. et al. The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J. 23, 2789-2799 (2004).
21. Jochum, W. et al. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat. Med. 6, 980-984 (2000).
22. Asangani, I. A. et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278-282 (2014).
23. Chapuy, B. et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24, 777-790 (2013).
24. Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533 (2011).
25. Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011).
26. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
27. Lockwood, W. W., Zejnullahu, K., Bradner, J. E. & Varmus, H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc. Natl. Acad. Sci. USA 109, 19408-19413 (2012).
28. Mertz, J. A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA 108, 16669-16674 (2011).
29. Ott, C. J. et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 120, 2843-2852 (2012).
30. Trabucco, S. E. et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin. Cancer Res. 21, 113-122 (2015).
31. Neale, G. et al. Molecular characterization of the pediatric preclinical testing panel. Clin. Cancer Res. 14, 4572-4583 (2008).
32. Houghton, P. J. et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr. Blood Cancer 49, 928-940 (2007).
33. Walkley, C. R. et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes. Dev. 22, 1662-1676 (2008).
34. Mutsaers, A. J. et al. Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA. Bone 55, 166-178 (2013).
35. Morton, C. L., Papa, R. A., Lock, R. B. & Houghton, P. J. Preclinical chemotherapeutic tumor models of common childhood cancers: solid tumors, acute lymphoblastic leukemia, and disseminated neuroblastoma. Curr Protoc Pharmacol. Chapter 14, Unit14 8 (2007).
36. Cheng, Z. et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin. Cancer Res. 19, 1748-1759 (2013).
37. Zippo, A. et al. Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. Cell 138, 1122-1136 (2009).
38. Yang, Z. et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 19, 535-545 (2005).
39. Krystof, V., Baumli, S. & Furst, R. Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target. Curr. Pharm. Des. 18, 2883-2890 (2012).
40. Mirabello, L., Troisi, R. J. & Savage, S. A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115, 1531-1543 (2009).
41. Lamoureux, F. et al. Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Nat. Commun. 5, 3511 (2014).
42. Nishida, Y., Knudson, W., Knudson, C. B. & Ishiguro, N. Antisense inhibition of hyaluronan synthase-2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity. Exp. Cell Res. 307, 194-203 (2005).
43. Zhao, Y. et al. Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing. Biochem. Biophys. Res. Commun. 390, 642-647 (2009).
44. Lee, D. H. et al. Synergistic Effect of JQ1 and Rapamycin for Treatment of Human Osteosarcoma. Int. J. Cancer 136, 2055-2064 (2015).
45. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528 (2011).
46. Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320-334 (2013).
47. Martin, M. P., Olesen, S. H., Georg, G. I. & Schonbrunn, E. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem. Biol. 8, 2360-2365 (2013).
48. Gorlick, R. et al. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr. Blood Cancer 59, 1266-1274 (2012).
49. Parry, D. et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol. Cancer. Ther. 9, 2344-2353 (2010).
50. Guha, M. Cyclin-dependent kinase inhibitors move into Phase III. Nat. Rev. Drug. Discov. 11, 892-894 (2012).
51. Martin, S. K. et al. NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J. Bone Miner. Res. 25, 2126-2137 (2010).
52. Semerad, C. L. et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 106, 3020-3027 (2005).
53. Singbrant, S. et al. Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood 117, 5631-5642 (2011).
54. Shah, O. J. et al. Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization. Proc. Natl. Acad. Sci, USA 107, 12634-12639 (2010).
55. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. Voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).
56. Chepelev, I., Wei, G., Tang, Q. & Zhao, K. Detection of single nucleotide variations in expressed exons of the human genome using RNA-Seq. Nucleic Acids Res. 37, e106 (2009).
57. Kuijjer, M. L. et al. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer 51, 696-706 (2012).
58. Jurado, S. et al. ATM substrate Chk2-interacting Zn2 + finger (ASCIZ) Is a bi-functional transcriptional activator and feedback sensor in the regulation of dynein light chain (DYNLL1) expression. J. Biol. Chem. 287, 3156-3164 (2012).